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Background: Atherosclerosis is a leading cause of mortality in the Western world, and plaque 
diagnosis is still a challenge in cardiovascular medicine. The main focus of this study was to 
make atherosclerotic plaques visible using targeted nanoparticles for improved imaging. Today 
various biomarkers are known to be involved in the pathophysiologic scenario of atherosclerotic 
plaques. One promising new candidate is the globular domain of the adipocytokine adiponectin 
(gAd), which was used as a targeting sequence in this study.
Methods: gAd was coupled to two different types of nanoparticles, namely protamine-
  oligonucleotide nanoparticles, known as proticles, and sterically stabilized liposomes. Both 
gAd-targeted nanoparticles were investigated for their potency to characterize critical scenarios 
within early and advanced atherosclerotic plaque lesions using an atherosclerotic mouse model. 
Aortic tissue from wild type and apolipoprotein E-deficient mice, both fed a high-fat diet, were 
stained with either fluorescent-labeled gAd or gAd-coupled nanoparticles. Ex vivo imaging was 
performed using confocal laser scanning microscopy.
Results: gAd-targeted sterically stabilized liposomes generated a strong signal by accumulating 
at the surface of atherosclerotic plaques, while gAd-targeted proticles became internalized and 
showed more spotted plaque staining.
Conclusion: Our results offer a promising perspective for enhanced in vivo imaging using 
gAd-targeted nanoparticles. By means of nanoparticles, a higher payload of signal emitting 
molecules could be transported to atherosclerotic plaques. Additionally, the opportunity is 
opened up to visualize different regions in the plaque scenario, depending on the nature of the 
nanoparticle used.
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Introduction
In recent years it has become evident that adipose tissue performs various active 
metabolic and endocrine functions by delivering proactive cytokines, known as 
adipocytokines.1,2 Among these are free fatty acids, adipsin, leptin, resistin, plas-
minogen activator inhibitor-1, tumor necrosis factor-α (TNF-α), and adiponectin.3 
Adiponectin consists of 247 amino acids, and is secreted specifically from differenti-
ated adipocytes. The primary sequence of adiponectin, a 30 kDa polypeptide, consists 
of a signal sequence followed by a nonconserved N-terminal domain, 22 collagen 
repeats, and a C-terminal globular domain (gAd) which is structurally related to 
  TNF-α.4 In circulating blood, adiponectin appears at concentrations of 2–30 µg/mL,2 
and is subjected either to collagen-induced formation of trimers, hexamers, and higher 
oligomerized structures, or to rapid cleavage of the primary adiponectin sequence into International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the collagen-like region and into gAd (17 kDa),3–5 which is 
found at lower levels (about 1% of total adiponectin) in the 
circulation.6 gAd has been shown to have potent metabolic 
effects, particularly in skeletal muscle.5 Furthermore, it has 
been shown to increase insulin-stimulated glucose uptake 
and to boost β-oxidation of fatty acids.7,8 Apart from these 
antidiabetic properties, gAd shows anti-inflammatory as well 
as anti-atherosclerotic effects.5,9  The latter are also associated 
with the ability of adiponectin to stimulate production of 
nitric oxide by endothelial cells.10 As is well-known, endothe-
lial damage induced by proinflammatory cytokines, such as 
TNF-α, has a crucial role in the formation of atherosclerosis. 
Endothelial damage leads to adhesion and penetration of 
monocytes into the endothelium, followed by transformation 
of macrophages into dangerous foam cells.2 In parallel, it 
has been shown that adiponectin treatment reduces the size 
of the area of atherosclerotic plaques throughout the intima 
or adventitia.11 Moreover, local treatment with adiponectin 
leads to inhibition of mRNA expression of  VCAM-1 and 
ICAM-1 in the abdominal aortic tissue of atherosclerotic 
rabbits.11
When considering diagnostic applications, it is important 
to note that adiponectin is detected only in injured but not in 
intact vascular walls.12,13 In unpublished data, we showed that 
gAd binds even more efficiently than full-length adiponectin 
to atherosclerotic plaques. In the present study, we exploited 
this superior binding affinity of gAd to atherosclerotic lesions 
using gAd as a targeting sequence attached to two different 
classes of nanoparticles.
The first type of nanoparticles we examined were 
protamine-oligonucleotide nanoparticles, known as   proticles. 
Proticles are biodegradable nanoparticles, which have 
been previously developed and characterized by our group 
for the delivery of various active compounds, including 
antisense oligonucleotides or small peptides.14–17 Proticles 
can be formulated by directed self-assembly of anionic 
and cationic biopolymers in combination with protamine, a 
cationic 32 amino acid peptide used in depot insulin. These 
nanoparticles can be coated with drug targeting sequences in 
a second production step.18 Proticles are nontoxic and show 
no   immunostimulatory properties.19
The second type of nanoparticles we tested were steri-
cally stabilized liposomes, which are frequently used as 
drug delivery systems and increasingly utilized for targeted 
imaging.20–22 Liposomes have several advantages because 
they are easily formulated using a flexible set of lipid 
building blocks for assembly. In general, they show high 
  biocompatibility, and polymer-grafted liposome preparations 
exhibit prolonged residence times in the circulation,23,24 and 
are reported to be nonimmunogenic.25,26
Each nanoparticle can be loaded with many signal emit-
ting molecules. Therefore, we expected to see a brighter 
signal within plaque areas compared with the signal, which 
is generated by fluorescence-labeled gAd (one dye molecule 
per protein). To test this hypothesis, we coupled gAd to the 
abovementioned colloidal nanocarriers. By confocal laser 
scanning microscopy, we monitored the ability of these 
  gAd-targeted nanoparticles to recognize, bind, and accumulate 
in atherosclerotic plaques in the aortic tissue of apolipoprotein 
E-deficient mice. The enrichment of signal emitting groups in 
the plaques would be a prerequisite for efficient, noninvasive in 
vivo molecular imaging using   gAd-targeted nanoparticles.
Materials and methods
Materials
Oligonucleotides, as well as Alexa-488-labeled oligonucle-
otides (Alexa-488-ON) were obtained from Biospring GmbH 
(Frankfurt, Germany). A noncoding random sequence, 5’ ACG 
TTG GTC CTG CGG GAA 3’, was found to assemble proticles 
efficiently by complexation with protamine free base (Sigma, 
Vienna, Austria). Protamine free base, cholesterol, and all other 
chemicals were purchased from Sigma in the highest avail-
able quality. Palmitoyl-oleoyl-phosphatidylcholine (POPC), 
polyethyleneglycol-conjugated distearyl-phosphatidyletha-
nolamine (DSPE-PEG2000), and functionalized lipids as 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide 
(polyethylene glycol)2000] (DSPE-Mal-PEG) and 1,2-
dipalmitoyl-sn-glycero-3-phosphothioethanol (DPP-TE) were 
purchased from Avanti Polar Lipids (Alabaster, AL). Milli-Q 
water was purified using a Milli-Q Plus system (Millipore, 
Vienna, Austria).
Recombinant mouse globular adiponectin was raised in 
Escherichia coli, and a monoclonal mouse anti-human adi-
ponectin antibody was used as the primary antibody (Atgen, 
Gyeonggi-do, South Korea). An Alexa Fluor 488-prelabeled 
rat anti-mouse CD68 antibody was used as a macrophage 
marker, and nonspecific rat anti-human IgG2a was used as 
the negative control (AbD Serotec, Dusseldorf, Germany). 
As a long wavelength emitting dye, Atto655 (Atto-Tec 
GmbH, Siegen, Germany) was used either as a maleimide-
functionalized label (Atto655-Mal) or as an amine-reactive 
carboxylic acid succinimidyl ester (Atto655-NHS).
Fluorescence labeling procedures
Labeling procedures for proteins and antibodies followed 
standard protocols recommended by the supplier of the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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reactive fluorophores (see www.atto-tec.com), with slight 
modifications in the molar ratios of dye to protein/antibody. 
In the case of gAd, labeling was performed by coupling of 
Atto655-Mal to the single cysteine residue of the protein 
using a 20-fold molar excess of dye under basic condi-
tions in phosphate-buffered saline 10 mM and 150 mM 
NaCl at pH 8.0. Rat anti-human IgG2a was labeled with 
amine-reactive Atto655-NHS, labeling the side chains of 
lysine residues under equimolar conditions with Atto655-
NHS in 150 mM bicarbonate buffer containing 5 mM 
ethylenediamine tetra-acetic acid at pH 8.3. All labeling 
procedures were carried out at room temperature, followed by 
extensive dialysis at 4°C to stop the reaction and to remove 
nonbound dye. Dialysis was performed in microdialysis 
buttons (Hampton Research, Aliso Viejo, CA) using dialysis 
membranes with a molecular weight cutoff of 5–50 kDa, 
depending on the molecular mass of the labeled protein.
Phospholipid labeling was performed using a four-fold 
molar excess of DPP-TE dissolved in methanol over Atto655-
Mal dissolved in dimethylsulfoxide. The reaction was per-
formed in phosphate-buffered saline by incubation overnight 
at 37°C. The coupling reaction mixture was analyzed by 
high-pressure liquid chromatography (Vydac®, polymer RP 
column; Grace, Deerfield, IL) and purified by numerous 
high-pressure liquid chromatography runs. The yield was 
about 79%. The product was dried and stored at -20°C.
Preparation of gAd-coated stealth 
liposomes
Liposomes consisted of POPC/cholesterol/DSPE-PEG2000 
(optionally functionalized with maleimide)/DPP-TE-Atto655 
(optional dye component) at molar ratios of 3/2/0.3/0.01. 
Liposomes (lipid content 30 mg/mL) were made using the 
dry film rehydration technique as described previously.27 gAd 
was thiolated with 2-iminothiolan in phosphate-buffered 
saline at pH 8.0 to react more efficiently with maleimide. 
After dialysis, 200 µg of gAd were added to preformed 
extruded liposomes (molar maleimide to protein ratio 30:1) 
in phosphate-buffered saline, at pH 8, and incubated over-
night at room temperature under constant slight agitation. 
The reaction was stopped by adding a 10-fold molar excess 
of β-mercaptoethanol. Subsequently, the blocking agent and 
nonbound protein were removed by extensive dialysis against 
10 mM phosphate-buffered saline, pH 7.4, using a dialysis 
membrane with a cutoff of 300 kDa. Due to the presence of 
fluorescence labels, the protein concentration was determined 
by the method of Starcher.28 The binding efficiency of protein 
to lipid was about 20%. These data and estimation of the 
theoretical number of lipids which form one single liposome 
(calculations based on liposome size and surface area per 
phospholipid molecule) allowed a rough quantification of 
the number of gAd molecules per liposome. The final ratio 
of protein to fluorophore was 1:5 (mol/mol).
Preparation of gAd-coated proticles
Proticles comprised of oligonucleotides or Alexa-488-ON 
and protamine free base were prepared in aqueous solution 
by mixing. The composition of proticles is given as mass 
ratio between the components in the sequence ON:protamine, 
eg, 1:3 corresponding to 100 µg/mL of oligonucleotides and 
300 µg/mL of protamine free base. Proticle formation occurred 
within the first few seconds of component incubation based 
on a self-assembly process, due to strong ionic interactions 
between oppositely charged biomolecules. Reproducibility 
of proticle formation was guaranteed by accurate mixing of 
equal volumes of the components with a pipette and vortexing 
for 5 seconds as described previously.15,17 Batch sizes were 
used in the range of 500–1000 µL proticle suspensions. The 
preassembled proticles were incubated with 150 ng/10 µg 
oligonucleotides of native or fluorescence-labeled gAd for 
1 hour at room temperature in an orbital shaker (300 rpm), 
and were immediately used for the subsequent staining 
experiments.
radioactive labeling of gAd
To determine the binding capacity of gAd to proticles, gAd 
was radiolabeled with I125. 500 µg gAd in phosphate-buffered 
saline (1 µg/µL) were mixed with 3.5 mL 170 mM bicarbon-
ate buffer (NaHCO3, pH 8.2) and concentrated using Amicon 
centrifugal filter devices with a cutoff of 3 kDa (Millipore, 
Carrigtwohill, Ireland). This step was repeated twice and 
the probe was finally concentrated to the start volume of 
500 µL. Photometric measurement of the protein concentra-
tion at 280 nm showed a loss rate of 30%. Then the probe 
was labeled with 0.5 mCi of 125I, vortexed, incubated with 
5 µL N-bromosuccinimide (1 mg/mL), vortexed again, and 
incubated for 10 minutes at room temperature, as described 
by Sinn et al.29 A Sephadex PD 10 column was equilibrated 
with 10 mM phosphate-buffered saline (pH 7.4), and the 
radiolabeled gAd was transferred to the column and eluted 
with 3.5 mL of the same buffer. To determine the free rather 
than adiponectin-associated radioactivity, 100 µL of adi-
ponectin solution was centrifuged in a Microcon filtration 
tube at 13,000 rpm for 20 minutes (Millipore, Decatur, IL; 
cutoff 3 kDa). The flow through was diluted (1:1000) and 
counted on a Perkin Elmer Wallac Wizard 1470 automatic International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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gamma counter (Waltham, MA). When free radioactivity 
reached a value less than 5% of total radioactivity, the   labeled 
adiponectin was used for proticle formation.
Nanocarrier characterization
The particle size (hydrodynamic diameter), broadness of 
size distribution (polydispersity index), and zeta potential 
(electrophoretic mobility) of the nanocarriers were deter-
mined using either the Malvern Zetasizer HSA3000 or the 
Nanosizer ZS (both from Malvern, Herrenberg, Germany). 
Samples were diluted with Milli-Q water and the measure-
ments were carried out at 25°C. Formulations, including 
proticles consisting of oligonucleotides (or Alexa-488-ON) 
and protamine free base (mass ratio ON:protamine 1:3), as 
well as gAd-coated proticles (mass ratio ON:protamine:gAd 
1:3:0.025) were investigated. Similarly, liposomes were 
measured as gAd-coated and noncoated formulations.
The shape and morphology of the nanoparticles were 
assessed by small-angle X-ray scattering or electron 
microscopy. Proticles, as well as gAd-coated proticles, 
were freeze-dried and sputtered with chromium (coating 
thickness approximately 9 nm) in a gas discharge apparatus 
(GEA005 specimen penetration energy about 10 eV) under 
argon atmosphere (about 8–10-2 Pa). Ultra high-resolution 
imaging was performed at low acceleration voltage using a 
Zeiss Ultra 55 field emission scanning electron microscopy 
with Gemini® technology (Graz University of Technology, 
Graz, Austria). This microscope provides a high efficiency 
in lens secondary electron detector for high-contrast surface 
imaging.
For the liposomes, transmission electron microscopic 
images were recorded using a Zeiss EM902 electron micro-
scope (Oberkochen, Germany) operated at an acceleration 
voltage of 50 kV . Briefly, 10 µL of the liposomal suspensions 
were applied to a carbon-over-pioloform-coated grid and incu-
bated for 1 minute. The excess was drawn off with filter paper 
and replaced immediately by 10 µL of ammonium molybdate 
solution (2% in phosphate-buffered saline, pH 7.4). Samples 
were incubated for 2 minutes, blotted, air-dried, and viewed 
using a magnification of 30,000×.
Qualitative proof for coupling was performed with 
uncoated and gAd-coated liposomes using native poly-
acrylamide gel electrophores is followed by Western blot 
analysis (data not shown) and small-angle X-ray scattering. 
Small-angle X-ray scattering curves were measured using 
a SWAX camera (System 3, Hecus X-ray Systems, Graz, 
Austria) mounted on a sealed X-ray tube generator from 
Seifert (Ahrensburg, Germany) that was operated at 50 kV 
and 40 mA. The X-ray beam was filtered for CuKα   radiation 
(λ = 0.1542 nm) using a nickel foil and a pulse height 
discriminator. Small-angle X-ray scattering patterns were 
recorded using a linear, one-dimensional, position-sensitive 
detector (PSD 50-M, Hecus X-ray Systems, Graz, Austria). 
The X-ray beam size was 0.5 mm × 3.5 mm (vertical to 
horizontal). Calibration of the small angle region was 
performed with silver stearate. The samples were filled 
into 1 mm thick, thin-walled quartz glass capillaries, and 
measured for 3,600 seconds at room temperature. The 
background corrected scattering curves were evaluated by 
the GAP program30 to determine the bilayer thickness from 
the corresponding electron density profiles.
The binding efficiency of gAd to preassembled 
proticles was evaluated with radiolabeled gAd. Three 
different concentrations, ie, 250, 500, and 1000 ng 
gAd/10 µg oligonucleotides, were incubated for 1 hour 
at room temperature in an orbital shaker (300 rpm). After 
centrifugation at 20,000 × g at 4°C for 2 hours (5804 R 
centrifuge; Eppendorf,   Hamburg, Germany), the binding 
efficiency was determined by counting the gamma radiation 
of the supernatant and pellet separately on a Perkin Elmer 
Wallac Wizard 1470 automatic gamma counter.
Animal experiments
All animal procedures were approved by the Ministry of 
Science and Research, Austria. Apolipoprotein E-deficient 
mice, aged 2–4 months, with a C57BL/6J genetic background 
(Charles River Laboratories, Brussels, Belgium) were fed 
on Western-type (21% XL) experimental food (Ssniff Spe-
zialitäten GmbH, Soest, Germany) for 2–3 months. At least 
three mice were used for each staining trial.   Age-matched 
C57BL/6J wild type mice (Medical University of Vienna, 
Austria) were used as the control strain. Due to the fact 
that these mice developed no atherosclerotic lesions, just 
one mouse was used as a negative control per staining trial. 
All experiments were performed independent of gender. 
Injured endothelium was defined as the activated endothelial 
layer covering the atherosclerotic lesions of apolipoprotein 
E-deficient mice. For each ex vivo staining trial, the mice 
were sacrificed randomly with an overdose of isoflurane 
(Abbott GmbH, Vienna, Austria). The chest was opened, 
the circulation was rinsed immediately with phosphate-
buffered saline (pH 7.4) for 15 minutes by perfusing the heart 
using an injection needle, and the vena cava was transected. 
The aorta, including the aortic arch, was dissected, cut open, 
washed with phosphate-buffered saline (pH 7.4), and incu-
bated in Krebs–Henseleit solution (118 mM NaCl; 25 mM International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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NaHCO3; 2.8 mM CaCl2 2 H2O; 1,17 mM MgSO4 7 H2O; 
4,7 mM KCl; 1,2 mM KH2PO4; 2 mg/mL glucose; pH 7.4) to 
sustain its physiological activity while blocking nonspecific 
binding reactions with 1% bovine serum albumin (Sigma) 
for 1 hour at room temperature. The samples were then incu-
bated with the fluorescence-labeled biomarker (20 µg/mL 
of Atto655-labeled gAd), antibodies (nonspecific rat anti-
human IgG2a, or 5 µg/mL of AF488-labeled anti-CD68 for 
positive control) or gAd-coated nanoparticles (2 mg/mL 
Atto655-labeled gAd-coated stealth liposomes, Atto655-
labeled stealth liposomes for negative control; 100 µg/mL 
AF488-labeled gAd-coated proticles or AF488-labeled 
gAd-Atto655-coated proticles and AF488-labeled proticles 
for negative control) for 1–2 hours at 37°C with shaking in 
the dark to avoid fluorochrome bleaching. Hoechst 33342 
fluorescence dye (1 µg/mL, Invitrogen, Carlsbad, CA) was 
added to stain the cell nuclei. Subsequently, the aortic sec-
tions were washed 3–4 times in phosphate-buffered saline 
(pH 7.4), put on a glass slide, covered with polyvinyl alcohol 
mounting medium containing 1,4-diazabicyclo[2.2.2]octane 
(DABCO, Sigma), adjusted under a stereomicroscope, and 
overlaid with a cover slip.
Fluorescence imaging by confocal  
laser scanning microscopy
All fluorescence and transmitted light images of the aortic 
samples (Z-stack images) were acquired with the LSM 510 
Meta Axiovert 200M Zeiss confocal system (Jena, Germany). 
Images were collected using a 40 × Plan-Neofluar 1.3 DIC 
oil immersion objective and a multitrack configuration, with 
which the Hoechst Alexa Fluor 488 and Atto655 signals were 
sequentially collected with BP 420–480 nm, BP 50–550 nm, 
and BP 679–743 nm filters after excitation with 405, 488, 
and 633 nm laser lines, respectively. In the sequential 
  acquisitions for all three channels, the Zeiss AIM software 
(v 4.2) was used. All confocal images were acquired with a 
frame size of 1024 × 1024 pixels averaged three times.
Results
Physicochemical characterization  
of gAd-coated nanoparticles
Proticles (mass ratio ON:protamine 1:3) showed a mean 
particle diameter of about 188 nm for uncoated and 263 nm 
for gAd-coated proticles (mass ratio ON:protamine:gAd 
1:3:0.025). An adequate size distribution with polydispersity 
values between 0.03 and 0.30, and zeta potential values of 
28.1 ± 3.9 mV for uncoated proticles and 16.7 ± 2.6 mV 
for gAd-coated proticles were recorded. For liposomes, 
the average particle diameter increased upon gAd coupling 
from about 100 nm (polydispersity index approximately 
0.04) to about 160 nm (polydispersity index approximately 
0.18), with zeta potentials decreasing from -9.4 ± 1.3 mV 
to -21.9 ± 1.2 mV . All data are summarized in Table 1.
Transmission electron microscopic images of liposomes 
showed spherical particles (Figure 1A), the integrity of which 
was preserved after ligand coupling, as indicated by the 
small-angle X-ray scattering data, which give an impression 
of bilayer thickness and organization. The scattering contribu-
tion of ligands coupled onto the surfaces of the liposomes 
is seen in the scattering profiles (Figure 1B). However, the 
bilayer lamellarity and thickness (d = approximately 3.6 nm) 
was not impaired by the ligand-coupling procedures. By anal-
ogy, the scanning electron microscopic images of the freeze-
dried proticle suspensions showed single, mostly spherical 
adiponectin-coated proticles (Figure 1C). Determination of 
binding efficiency using I125-labeled gAd showed a maximum 
coupling efficiency of approximately 150 ng gAd/10 µg 
  oligonucleotides (Figure 1D).
Table 1 Nanoparticle size, polydispersity index, and zeta potential of unloaded and gAd-coated nanoparticles. The nanoparticle 
size (hydrodynamic diameter), polydispersity index, and zeta potential of two different preparations were determined using photon 
correlation spectroscopy. In this study, unloaded proticles (ON:protamine 1:3), gAd-coated proticles (ON:protamine:gAd 1:3:0.025) 
as well as plain or gAd-coated liposomes were characterized concerning these parameters. results express mean values ± standard 
deviations from six measurements for each preparation
Samples Mass ratio Hydrodynamic  
diameter (nm)
Polydispersity  
index
Zeta  
potential (mV)
pH value
ON/protamine 1:3 188.1 ± 13.2 0.03 ± 0.02 28.1 ± 3.9 9.36 ± 0.20
ON/protamine/gAd 1:3:0.025 263.1 ± 27.2 0.30 ± 0.09 16.7 ± 2.6 9.18 ± 0.09
POPc/DsPe-Peg2000/
cholesterol
98.4 ± 6.5  
(n = 8)
0.04 ± 0.02 -9.4 ± 1.3 7.4
POPc/DsPe-Peg2000- 
mal-gAd/cholesterol
20:1 
(lipid to protein)
165 ± 13.5 
(n = 4)
0.11 ± 0.05 -21.9 ± 1.2 7.4
Abbreviations: ON, oligonucleotides; gAd, globular domain of the adipocytokine adiponectin; POPc, palmitoyl-oleoyl-phosphatidylcholine; DsPe-Peg2000, polyethylene 
glycol conjugated distearyl-phosphatidylethanolamine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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staining of atherosclerotic plaques with 
gAd-coated stealth liposomes
The aortas were incubated with Atto655-labeled stealth lipo-
somes because no interfering autofluorescence signal was 
observed at λext = 633 nm for unstained blank sections, neither 
from the whole uninjured aortic tissue nor from the scanned 
atherosclerotic plaques (Figure 2A). We found a dotted fluo-
rescence signal pattern on the aortic sections of apolipoprotein 
E-deficient mice, particularly in the plaque regions and in the 
less injured surrounding area (Figure 2B). Sections from wild 
type mice were stained as controls, showing only weak signals 
at the generally uninjured aortic surface. A similar low stain-
ing pattern was observed for gAd-coated stealth liposomes 
on the uninjured sections from wildtype mice and at less 
injured aortic sections of apolipoprotein E-deficient mice. In 
contrast, a strong signal was detected from the gAd-coated 
stealth liposomes at atherosclerotic plaque areas (Figure 2C). 
The staining signal of gAd-coated liposome partially colocal-
izes with CD68-stained monocytes/macrophages, which were 
detected at the plaque surface (Figure 3).
staining of atherosclerotic plaques  
with gAd-coated proticles
Next, we examined the staining features of the proticles. 
Sections from the inner aortic surface of apolipoprotein 
E-deficient and C57Bl6/J wild type mice were imaged by 
confocal laser scanning microscopy, unstained or stained 
with either AF488-labeled proticles or gAd-coated AF488-
labeled proticles. Unstained blank sections showed a weak 
autofluorescence signal at λext = 488 nm detected from the 
whole uninjured aortic tissue. In the specific atherosclerotic 
plaque area, only a small portion of fluorescence emitting 
inclusions were observed, whereas neither the plaques nor 
the plaque surface showed obvious interference caused by the 
autofluorescence signal of the tissue (Figure 4A). To exam-
ine the nonspecific binding of proticles to aortic tissue, we 
incubated aortic sections from apolipoprotein E-deficient and 
wildtype mice with AF488-labeled proticles. We observed a 
weak staining signal on the whole aortic surface. However, on 
atherosclerotic plaque areas, we saw a stronger spotted fluo-
rescence signal pattern (Figure 4B). Using CD68   staining, we 
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Figure 1 characterization of gAd-coated nanoparticles. A) Liposomes. A representative transmission electron microscopy image (white bar indicates 100 nm) highlights the 
size distribution and morphology of liposomes. B) small angle X-ray scattering of uncoated and gAd-coated liposomes. The intrinsic lipid bilayer parameter (eg, lamellarity 
and thickness) derived from SAXS curves were not affected by ligand coupling (uncoated liposome [black line], fluorescent-labeled liposome [dotted line] and gAd-coupled 
liposome [dashed line]). The contribution of dye/protein to the scattering intensity is seen at a low q-range (marked by a frame). The best fit to the data obtained from 
deconvolution is shown on the right side. The calculated electron density profile, that allows for the determination of the bilayer thickness, estimated as phospholipid head-
to-head group distance, d, is shown as an inset on the left side. C) Proticles. scanning electron microscopy images of freeze-dried adiponectin-coated proticles (mass ratio 
ON:protamine:adiponectin 1:3:0.025; white bar indicates 250 nm). D) Coating efficiency of adiponectin to proticles. Preassembled proticles were incubated with various 
amounts of radiolabeled gAd. Calculation of coating efficiency as percentage of deployed adiponectin showed a constant binding amount of gAd to oligonucleotides (analysis 
of variance, P , 0.05, n = 3). 
Abbreviations: gAd, globular domain of adiponectin; ON, oligonucleotides.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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C
Figure 2 The staining signal of liposomal nanoparticles at atherosclerotic plaques is enhanced by globular adiponectin. Aortic sections of apolipoprotein E-deficient and 
c57Bl6/J wild type mice were incubated with Atto655-labeled stealth liposomes as controls (B), or with gAd-coupled Atto655-labeled liposomes (C). Blank sections are 
shown in (A). The upper panels correspond to plaque regions, while the lower panels show the signals in artery sections without plaques. The inserts (B, C) show the weak 
fluorescence signals from stained wild type aortic tissue. Transmitted light images of the aortic sections are shown in (A) (inserts). The insert between (B) and (C) displays 
the accumulation of Atto655-labeled gAd at atherosclerotic plaques for comparison. sections were placed between a glass slide and a cover slip and visualized by confocal 
laser scanning microscopy (fluorescence and transmitted light). For each visualization, a series of 20–30 fluorescence images in Z (1 µm consecutive intervals) were projected 
in a single image. Both bars indicate 50 µm. 
Abbreviation: gAd, globular domain of adiponectin.
A
B
gAd-Lipo-Atto655 CD68-AF488 Merge
Merge
Figure 3 Costaining for anti-CD68. Aortic sections of apolipoprotein E-deficient mice were incubated with Atto655-labeled gAd-coupled stealth liposomes and costained 
with an Alexa Fluor 488 ready-labeled mouse anti-cD68 antibody. A) Three-dimensional fluorescence images from an atherosclerotic plaque. Bar indicates 50 µm. B) Vertical 
fluorescence image of the same plaque. Vertical bar indicates 15 µm. The yellow signal in the merged images indicates the colocalization of gAd liposomes (red signal) and 
anti-cD68 (green signal). 
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found a colocalization of the   fluorescence signals   (Figure 4, 
middle panel), which is indicative of internalization of the 
proticles, most likely by macrophages. To investigate the 
selective targeting ability of the proticles, aortic sections were 
incubated with gAd-coated proticles. In the confocal laser 
scanning microscopy images, we observed strong enhance-
ment of the fluorescence signal, still showing the spotted 
fluorescence pattern observed for nontargeted proticles   
(Figure 4C).
signal enhancement by gAd-targeted 
nanoparticles in comparison  
with free gAd
gAd-coated liposomes behaved in a manner similar to that 
of free Atto655-labeled gAd (flu-gAd), because they did not 
penetrate into the atherosclerotic plaque, but accumulated 
at the plaque surface, and thereby produced a pronounced 
increase in signal intensity when compared with flu-gAd 
(Figures 5A and 5B).
Flu-gAd coupled with Alexa Fluor 488-labeled proticles 
showed a considerably altered staining pattern in the plaque 
scenario as compared with free uncoupled flu-gAd. As 
already mentioned above, the staining pattern changed to a 
spotted macrophage-specific staining, which was markedly 
amplified compared with that of the uncoated proticles. Most 
interestingly, gAd-coated proticles penetrated the plaque 
deeper than did free flu-gAd (Figure 5C). As a negative 
control, aortic sections from apolipoprotein E-deficient mice 
were stained with Atto655-labeled nonspecific rat IgG. Only 
traces of unspecific IgG accumulation on the atherosclerotic 
plaques were detected (Figure 6).
Discussion
Drug delivery and noninvasive imaging applications with the 
help of targeted nanoparticles are becoming more and more 
important in modern medicine.31,32 Beyond this, nanoparticles 
offer new possibilities as homing devices for various drugs 
or contrast agents. Although cancer therapy and cancer 
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Figure 4 The staining signal of globular adiponectin at atherosclerotic plaques is altered by protamine-oligonucleotide-based nanoparticles. Aortic sections of apolipoprotein 
E-deficient and C57Bl6/J wild type mice were incubated with Alexa Fluor 488-labeled proticles for control (B), or with gAd-coupled, Alexa Fluor 488-labeled proticles (C). 
Blank sections are shown in (A). The upper panels correspond to plaque regions, while the lower panels show the signals in artery sections without plaques. The inserts (B, 
C) show the weak fluorescence signals from stained wild type aortas. Transmitted light images of the aortic sections are shown in (A) (inserts). The inserts in (B) show the 
accumulation of proticles (green signal) inside a CD68-verified macrophage (M, blue signal). Both bars in (A) indicate 50 µm, bar in the first insert in (B) indicates 5 µm. 
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diagnostics are still dominating the field, the detection of 
atherosclerotic plaques is an equally attractive endeavor in 
the prevention of cardiovascular diseases.33,35 Atherosclerosis 
is a chronic disease in which inflammatory processes are the 
driving forces for the formation, progression, and rupture of 
atherosclerotic plaques.36 One key event in atherosclerosis is 
the differentiation of monocytes into lesional macrophages, 
a process driven by inflammatory cascades.37 Consequently, 
several mediators involved in the inflammatory process dur-
ing the progression of atherosclerosis have been suggested as 
potential biomarkers to recognize atherosclerotic lesions.34 In 
addition, adipocytokines, such as adiponectin, are suggested 
as promising candidates.38
In the present study, we chose the globular domain of 
adiponectin as a targeting sequence, because we had already 
shown that free gAd detects atherosclerotic lesions very 
well (unpublished data). We found that gAd accumulated in 
the endothelial cells and fibrous cap area of atherosclerotic 
plaques. Here we address the question of whether signal 
enhancement, which is necessary for high-resolution detec-
tion in vivo, can be achieved when gAd is coupled with 
nanoparticles serving as transporters of signal-emitting 
molecules. Specifically, we have tested two different kinds 
of nanoparticles, namely stealth liposomes and proticles, and 
used an apolipoprotein E-deficient mouse model fed on a 
Western-type diet as a model system for atherosclerosis.
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Figure 5 Plaque imaging of gAd-coupled nanoparticles in comparison with uncoupled gAd. Aortic sections of apolipoprotein E-deficient mice were incubated with (A) Atto655-
labeled gAd, (B) gAd-coupled Atto655-labeled liposomes, or (C) Atto65-labeled gAd coupled to Alexa Fluor 488-labeled proticles. The pictures show vertical fluorescence and 
transmitted light images from atherosclerotic plaques similar in size. Nuclei were costained with hoechst nucleus dye. The yellow signal in the merged image in (C) indicates 
the colocalization of gAd (red signal) and proticles (green signal). The dashed white lines mark the boundary layer of the plaques. Vertical bar indicates 15 µm. 
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Liposomes are one of the most widely studied classes of 
nanoparticles. They are composed of biologically degrad-
able phospholipid molecules, and in aqueous solution they 
typically assemble to form closed bilayer structures.39 They 
are easy to handle, and offer a unique variety of combina-
tion possibilities because of their overall size and charge. 
Surface coating with polymers like polyethylene glycol 
significantly enhances their circulation time because they 
are not rapidly cleared by the reticular endothelial system.23 
Likewise, functionalized groups can be attached to the distal 
end of the polyethylene glycol chains for coupling of active 
molecules.40 Alternatively, different labels can be linked to 
or incorporated into the liposomes.41,42
Proticles are less well explored, but have already proven 
to be very successful in drug targeting. They can be coated 
with targeting ligands, such as small peptides, and also with 
larger proteins like apolipoprotein A-1.18 In an earlier study, 
we demonstrated improved permeability of the blood–brain 
barrier for proticles with apolipoprotein coating. Recently, 
we investigated the targeting effect of vasoactive intestinal 
peptide, which was incorporated into the proticle matrix. 
Using this system, we could demonstrate a targeted associa-
tion of proticles on the cell surface in vitro and a specific 
localization of proticles into vasoactive intestinal peptide 
receptor-positive lung tumor material ex vivo.43
In the present study, both kinds of nanoparticles were 
coated with the same targeting sequence, either by covalent 
attachment of gAd to the polyethylene glycol spacer on 
the surface of liposomes or electrostatically bound to the 
surface of the proticles. A comparably high amount of gAd 
was attached to the nanocarriers, corresponding to about 
15 ng gAd per µg of oligonucleotides or, on average, 65 
thiolized gAd molecules per liposome. Whereas the size of 
the liposomes was kept below 200 nm with a negative zeta-
potential, proticles were somewhat larger and had a positive 
net surface charge.
To study the potential for molecular imaging, we have 
performed confocal laser scan fluorescence microscopy 
to evaluate the efficiency of the targeted nanocarriers to 
recognize atherosclerotic plaques ex vivo. Both classes 
of gAd-targeted nanoparticles led to remarkable signal 
  enhancement compared with free gAd, while untargeted 
Unspec rat IgG
TLI Merge
CD68
Figure 6 Negative control staining. Three-dimensional fluorescence and transmitted light images from an atherosclerotic plaque. Aortic sections of apolipoprotein E-deficient 
mice were stained with Atto655-labeled unspecific rat IgG and costained with Alexa Fluor488 ready-labeled mouse anti-CD68. Bar indicates 50 µm.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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proticles showed fewer untargeted liposomes, and had 
almost no binding affinity for atherosclerotic plaques. The 
most striking feature of our study was that the two classes 
of targeted nanoparticles demonstrated distinct differences 
in their binding/  internalization behavior, strongly depending 
on the nature of the nanocarrier.
Apart from chemical composition, particle size, and mor-
phology, surface charge is an important parameter influencing 
interactions and uptake of macromolecules.44 In general, the 
phagocytic activity of macrophages is higher for anionic than 
for cationic nanoparticles.45,46 Neutral nanoparticles showed 
the lowest uptake, at least in vitro.47,48 In our study, we used 
positively charged proticles and slightly negatively charged 
liposomes. After gAd (isoelectric point 5.4) coupling, the 
surface net charge was further decreased. Hence, the observed 
differences in the interaction mechanisms of nanoparticles 
with the plaque could well be charge-dependent. However, 
negatively charged, sterically stabilized gAd-coated liposomes 
accumulated at the outer surface of the plaque, similar to free 
flu-gAd, and generated a strong signal enhancement at the 
plaque surface, ie, the so-called fibrous cap area. The targeted 
liposomes colocalized with monocytes/macrophages detected 
in this region by anti-CD68 costaining. Positively charged 
proticles adhered more tightly to the arterial wall of athero-
sclerotic plaques, probably due to the enhanced permeability 
caused by the loss of the endothelial glycocalyx,49 and were 
readily taken up by macrophages as proven by anti-CD68 
costaining. This observed uptake by surface monocytes/
macrophages and subsequent internalization in intraplaque 
macrophages, which represent most of the macrophages 
in atherosclerotic lesions, was markedly enhanced by gAd 
targeting. In apolipoprotein A-/- mice, mainly Gr1+/Ly6Chi 
monocytes occur.50 These monocytes were reported to adhere 
to activated endothelium, infiltrate lesions, and become 
atherosclerotic macrophages.51 Hence, the gAd-targeted 
proticles could be a useful device for further cell tracking 
experiments and exploring the progression of inflammation 
in atherosclerosis, while gAd-targeted liposomes represent 
promising markers for imaging of the fibrous cap.
Conclusion
Our results demonstrate the potential of gAd-targeted nano-
particles to recognize atherosclerotic lesions in the arterial 
wall. The approach taken here could offer, beyond diagnostic 
purposes, therapeutic drug targeting options for the future. 
However, using one specific biomarker coupled to diverse 
nanoparticles creates different imaging characteristics. 
This, in turn, offers the possibility to probe different regions 
within the same plaque scenario. At this point, it appears 
that a rational combination of diverse nanoparticles could be 
advantageous for the evaluation of novel targeting sequences 
to image inflammatory sites or even to discriminate between 
stable and vulnerable plaques.
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